COVID-19: the immune response, immunopathology and vaccines
- Topic
COVID-19 turns severe when early interferon defence fails and later inflammation runs wild; vaccines train antibodies and T cells against the spike protein.
What it is
SARS-CoV-2 enters cells through ACE2 using its spike protein. Mild disease reflects a quick type I interferon response followed by antibodies and T cells. Severe disease is linked to a weak or delayed interferon response, then excessive inflammation with IL-6, activated monocytes, neutrophils, endothelial injury and clotting. Vaccines induce neutralising antibodies and T cells against spike; antibodies wane and variants escape them, but T cells still protect against severe disease.
Key facts
- Neutralising autoantibodies against type I interferons are found in a notable minority of people with critical COVID-19, more often in older men.
- Rare inborn errors of TLR3 and IRF7 interferon pathways also predispose to life-threatening disease.
- Omicron and later variants escape many neutralising antibodies, which is why boosters were updated.
- Hybrid immunity (infection plus vaccination) gives broad protection.
Step by step
- Spike binds ACE2 on airway cells; the host protease TMPRSS2 helps the virus fuse and enter.
- Infected cells sense viral RNA and make type I and III interferons, which limit spread.
- If interferon is late or blocked (autoantibodies, inborn errors), the virus replicates widely in the lungs.
- Monocytes and macrophages release IL-6, IL-1 and TNF; neutrophil traps and endothelial injury promote clots.
- Lymphopenia, high CRP, ferritin and D-dimer mark severe disease; alveolar damage causes hypoxaemia.
- Neutralising antibodies to the receptor-binding domain and CD4/CD8 T cells clear the virus and leave memory.
Mild versus severe COVID-19: what differs
| Feature | Mild course | Severe course |
|---|---|---|
| Early interferon | Fast and strong | Delayed or blocked (anti-interferon autoantibodies, TLR3/TLR7/IRF7 defects) |
| Viral load in lung | Controlled early | High, spreads to alveoli |
| Inflammation | Limited | IL-6, IL-1, TNF, activated monocytes and neutrophils, clotting |
| Blood markers | Near normal | Lymphopenia, high CRP, ferritin, D-dimer |
| Who is at risk | Most vaccinated and young people | Older age, unvaccinated, immunosuppressed, men more often |
| What helps most | Early antivirals in high-risk outpatients | Dexamethasone for oxygen need; IL-6 receptor or JAK blockade in selected patients |
Clinical notes
- Dexamethasone reduces mortality in hospitalised patients needing oxygen; IL-6 receptor blockers or JAK inhibitors are added in selected patients.
- Early antivirals help high-risk outpatients; earlier monoclonal antibodies lost activity against newer variants.
- Vaccine platforms used worldwide, including in Colombia: mRNA, adenoviral vector, protein subunit and inactivated vaccines.
- Rare vaccine immune events: myocarditis (mainly young males after mRNA vaccines) and thrombosis with thrombocytopenia after adenoviral vector vaccines.
- Multisystem inflammatory syndrome in children appears weeks after infection with Kawasaki-like features.
Common traps
- Severe COVID-19 means the immune system was too weak throughout: the early interferon phase is weak, the late inflammatory phase too strong.
- Steroids help every patient with COVID-19: dexamethasone helps those needing oxygen, but not people with mild disease.
- Falling antibodies mean vaccine protection is gone: T cells and memory B cells still protect against severe disease.
- Vaccine myocarditis and post-vaccine thrombosis come from the same vaccines: myocarditis is mainly after mRNA, thrombosis with thrombocytopenia after adenoviral vectors.
Test yourself
Think of the answer, then tap the question to see it.
Why does dexamethasone help hospitalised patients who need oxygen but not those with mild COVID-19?
Severe disease is driven by late hyperinflammation, which steroids damp; in mild early disease the problem is the virus, and suppressing immunity does not help.
A previously healthy man in his 70s develops critical COVID-19. Which autoantibodies might explain the failure of early defence?
Neutralising autoantibodies against type I interferons, which block the early antiviral response.
Variants escape many neutralising antibodies, yet vaccinated people still rarely develop severe disease. Why?
T cells recognise many conserved peptides across the virus, so variants escape them far less, and they limit spread in the lung.
Connections
Microorganisms1
In Pharmacology2
Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.
Sources: COVID-19 (Coronavirus Disease 2019) (MedlinePlus, US National Library of Medicine, 2024); Chapter 1: Principles of Vaccination (Centers for Disease Control and Prevention (Pink Book), 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
